Urothelial Changes in UCPPS: Urinary Proteomes and Biomarkers

$130,015U01FY2009DKNIH

University Of Washington, Seattle WA

Investigators

Linked publications & trials

Paper 38270336 Paper 38247366 Paper 38109700 Paper 37278657 Paper 37144687 Paper 37001828 Paper 36845296 Paper 36630590 Paper 36279178 Paper 35961564 Paper 35060778 Paper 35021046 Paper 34774759 Paper 34309138 Paper 34029685 Paper 33604963 Paper 33535797 Paper 33347771 Paper 33337593 Paper 33199816 Paper 33027702 Paper 33026902 Paper 32578257 Paper 32447589 Paper 32294397 Paper 32293947 Paper 31884113 Paper 31794439 Paper 31220089 Paper 31091120 Paper 31050659 Paper 31028455 Paper 31017816 Paper 31012513 Paper 30986484 Paper 30917614 Paper 30682464 Paper 30560936 Paper 30517112 Paper 30452963 Paper 30212850 Paper 29863527 Paper 29604315 Paper 29307682 Paper 29288643 Paper 28992894 Paper 28692006 Paper 28528930 Paper 28373134 Paper 28328579 Paper 28263447 Paper 27842046 Paper 27408791 Paper 27312318 Paper 27275736 Paper 27131464 Paper 26585679 Paper 26497778 Paper 26460744 Paper 26410734 Paper 26271474 Paper 26192257 Paper 26106574 Paper 26099876 Paper 26010458 Paper 25771510 Paper 25711200 Paper 25599234 Paper 25596358 Paper 25463989 Paper 25444992 Paper 25365794 Paper 25242566 Paper 25132239 Paper 25085119 Paper 25085007 Paper 24681331 Paper 24336429 Paper 23955075 Paper 23718576 Paper 23650302 Paper 23619478 Paper 23234637 Paper 22782281 Paper 22486937 Paper 21795004 Paper 20430229 Paper 20338816 Paper 19788469 Paper 19758633

Abstract

These proposed studies directly address 3 RFA objectives. First, we offer a basic/translational science study that considers local urogenital tract factors in the pathogenesis of UCPPS. Second, we address RFA request for studies to identify and validate biomarkers for UCPPS. Our strategy uses cutting-edge proteomic analysis of urine specimens from patients with IC/PBS and CP/CPPS in a new approach to identify and validate new biomarkers that potentially could improve diagnosis, predict UCPPS natural history, and predict or measure response to treatment. Third, this work also addresses the RFA priority to elucidate the pathogenesis of UCPPS. These protein/peptide markers may act via specific cellular pathways important to UCPPS pathology. Notably, if successful, this technology can be exported across the Network and could establish a foundation for future clinical trials and for more targeted therapies to treat specific urothelial defects.

View original record on NIH RePORTER →